Related references
Note: Only part of the references are listed.Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
Young Ho Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2020)
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: amatching-adjusted indirect comparison
B. Fautrel et al.
RMD OPEN (2020)
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
Akio Kawabe et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Sae Ochi et al.
ARTHRITIS RESEARCH & THERAPY (2020)
The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
Yoshiya Tanaka
RHEUMATOLOGY (2019)
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman et al.
RHEUMATOLOGY (2019)
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
S-C Bae et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2019)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching
Satoshi Kubo et al.
CLINICAL IMMUNOLOGY (2018)
Janus Kinase inhibitor Baricitinib Modulates human innate and adaptive immune system
Satoshi Kubo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study
D. S. Courvoisier et al.
EBIOMEDICINE (2016)
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
Vibeke Strand et al.
RMD OPEN (2016)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ARTHRITIS AND RHEUMATISM (2011)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman et al.
JOURNAL OF IMMUNOLOGY (2010)
Growth mixture modeling: A method for identifying differences in longitudinal change among unobserved groups
Nilam Ram et al.
INTERNATIONAL JOURNAL OF BEHAVIORAL DEVELOPMENT (2009)
Epidemiology and burden of illness of rheumatoid arthritis
TK Kvien
PHARMACOECONOMICS (2004)
Share Paper
